InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
8
Disclosed sells
0
T+90 hit rate
13%
T+90 mean return
-25.8%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Young David, Chief Executive Officer. Insider active across 1 company, notably Processa Pharmaceuticals, Inc.. In total, 18 filings have been logged. Breakdown: 8 buys · 0 sell. Total volume traded: €368k. Activity tracked since 23 June 2021. The latest transaction was filed on 27 January 2025 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
17,272 sharesCommon StockSEC:0000897069-25-000787:0
124,500 shares@ US$0.797520.8% of flowCommon StockSEC:0000897069-25-000132:0
Ideal exit: 24 Oct 2025 (T+270)
1,675 sharesCommon StockSEC:0000897069-24-001606:0
1,675 sharesCommon StockSEC:0000897069-24-000925:0
21,000 shares@ US$2.453610.5% of flowCommon StockSEC:0000897069-24-000269:0
Ideal exit: 3 Nov 2024 (T+270)
20,000 shares@ US$2.525210.3% of flowCommon StockSEC:0000897069-24-000253:0
Ideal exit: 2 Nov 2024 (T+270)
155,277 shares@ US$0.299.4% of flowCommon StockSEC:0000897069-23-001460:0
142,000 shares@ US$0.247.0% of flowCommon StockSEC:0000897069-23-001444:0
40,000 shares@ US$0.806.5% of flowCommon StockSEC:0000897069-23-000716:0
Ideal exit: 8 Mar 2024 (T+270)
20,000 shares@ US$0.54992.2% of flowCommon StockSEC:0000897069-23-000278:0
Ideal exit: 9 Jan 2024 (T+270)
20,000 shares@ US$0.522.1% of flowCommon StockSEC:0000897069-23-000269:0
Ideal exit: 6 Jan 2024 (T+270)
18,750 shares@ US$0.803.1% of flowCommon StockSEC:0001567619-23-002398:0
9,250 shares0Common StockSEC:0001567619-22-016597:0
7,601 sharesCommon StockSEC:0001567619-22-015306:0
7,601 sharesCommon StockSEC:0001567619-21-014741
7,601 sharesCommon StockSEC:0001567619-21-014741:0
10,000 shares@ US$7.671614.1% of flowCommon StockSEC:0001567619-21-012540
Ideal exit: 20 Mar 2022 (T+270)
10,000 shares@ US$7.67160.99% mcap50.0% of flowCommon StockSEC:0001567619-21-012540:0
Ideal exit: 20 Mar 2022 (T+270)
18 of 18 declarations
About Young David
David Young is the Chief Executive Officer of Processa Pharmaceuticals, Inc. He is responsible for the strategic and operational direction of the company. His leadership and expertise in the pharmaceutical sector are essential in guiding Processa Pharmaceuticals, Inc. towards its growth objectives.
